VapAria is a pre-clinical specialty pharmaceutical company. Our operations are focused on the development and commercialization of methods and medicants to address and reduce the harms associated with chronic conditions with novel, vapor-centric, inhalable approaches to pain management, appetite suppression, mood enhancement, smoking and various sleep disorders and doing with patented device methods and patented drug approaches.
Prior to forming VapAria Solutions in 2010, our management had more than 25 years' collective experience in vaporization and vapor delivery of medicants, having been partners in a joint venture with pioneers in the industry and having had undertaken significant work internationally researching and developing products, shepherding them through the patent process and introducing them into the U.S. wholesale and retail supply chain. Our management, through the Chong Corporation, a common control entity that is the licensor of the intellectual property rights described below, has built an extensive and robust portfolio of intellectual property that includes patented and patent-pending methods of vaporization and patented and patent-pending medicants and herbal remedies identified for their effectiveness and suitability to address our target markets.
Our initial goal was to leverage rights we acquired in December 2013 from an affiliate which are described below to develop and successfully launch a product in partnership with well-capitalized and experienced industry participants based on our exclusive license and exclusive options to license patented and patent-pending technologies and formulations designed to significantly improve on current electronic nicotine delivery systems and other consumer products in the marketplace. Since mid-2015 and continuing into the first quarter of 2019, in addition to discussions with third party financing sources, we have engaged in substantive discussions with several U.S. and international companies which have expressed an interest in our licensed technology in pursuit of this strategy.